Skip to main content

LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Publication ,  Conference
Armstrong, AJ; Iguchi, T; Azad, AA; Szmulewitz, RZ; Holzbeierlein, J; Villers, A; Alcaraz, A; Alekseev, BY; Shore, ND; Petrylak, DP; Zohren, F ...
Published in: Annals of Oncology
September 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2021

Volume

32

Start / End Page

S1300 / S1301

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Iguchi, T., Azad, A. A., Szmulewitz, R. Z., Holzbeierlein, J., Villers, A., … Stenzl, A. (2021). LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In Annals of Oncology (Vol. 32, pp. S1300–S1301). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.2101
Armstrong, A. J., T. Iguchi, A. A. Azad, R. Z. Szmulewitz, J. Holzbeierlein, A. Villers, A. Alcaraz, et al. “LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In Annals of Oncology, 32:S1300–1301. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.2101.
Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev BY, Shore ND, Petrylak DP, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. Elsevier BV; 2021. p. S1300–S1301.

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2021

Volume

32

Start / End Page

S1300 / S1301

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis